학술논문
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
Document Type
article
Author
Jacobo Rogado; Nuria Romero-Laorden; José Miguel Sanchez-Torres; Ana María Ramos-Levi; Vilma Pacheco-Barcia; Ana Isabel Ballesteros; Reyes Arranz; Alicia Lorenzo; Pedro Gullon; Ana Garrido; José María Serra López-Matencio; Olga Donnay; Magdalena Adrados; Pablo Costas; Javier Aspa; Arantzazu Alfranca; Rebeca Mondejar; Ramon Colomer
Source
OncoImmunology, Vol 9, Iss 1 (2020)
Subject
Language
English
ISSN
2162-402X
2162402X
2162402X
Abstract
Immunotherapy is an effective treatment in advanced cancer, although predictors of response are limited. We studied whether excess weight influences the efficacy outcomes of immunotherapy. We have also evaluated the combined prognostic effect of excess weight and immune-related adverse events (irAEs). Efficacy of anti-PD-1 treatment was evaluated with both objective radiological response (ORR) rate and progression-free survival (PFS), and toxicity with irAEs. We studied the association between excess weight and ORR, PFS or irAEs. 132 patients diagnosed with advanced cancer were included. Median body mass index (BMI) was 24.9 kg/m2. 64 patients had normal weight (BMI